clinical trial · NCT06917872
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
Boehringer Ingelheim·phase1·completed·n = 20
HealthyBI 1291583erythromycin
brief summary
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.
started
Apr 29, 2025
primary completion
Sep 9, 2025
completion
Sep 9, 2025
last updated
Sep 16, 2025
official title
An Open-label, Fixed-sequence, Two-period Phase I Trial to Evaluate the Effect of Multiple Oral Doses of Erythromycin, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of BI 1291583 at Steady State in Healthy Male and Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol